-Reuters
Arcturus Therapeutics Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants
Late-breaking data presented at 9th ESWI Influenza Conference in ValenciaArcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global late-stage clinical messenger RNA medicines company focused